Equities

Aptamer Group PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Aptamer Group PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)0.9111
  • Today's Change-0.039 / -4.09%
  • Shares traded1.88m
  • 1 Year change+124.97%
  • Beta1.3393
Data delayed at least 20 minutes, as of Feb 10 2026 11:05 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Aptamer Group plc is a United Kingdom-based global developer of aptamer-based ligands. The Company develops custom affinity binders through its Optimer platform to enable new approaches in therapeutics, diagnostics and research applications. The Company's Optimer platform delivers aptamer tools that are enabling researchers and developers across the spectrum of the life sciences. Its Optimer binders have been developed for a range of applications, including therapeutic inhibitors and modulators, drug delivery vehicles, protein purification and separation, biomarker screening and validation, in vitro research, quality control analysis, pharmacokinetic and drug assays, and in vitro diagnostic assays. Its Aptamer Diagnostics division uses the Company's technology to support the development of diagnostic platforms, such as proteomics, lateral flow devices, biosensors and immunoassays, such as enzyme-linked immunosorbent assay (ELISA).

  • Revenue in GBP (TTM)1.20m
  • Net income in GBP-2.42m
  • Incorporated2014
  • Employees31.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Proteome Sciences plc4.53m-3.33m6.05m36.00------1.34-0.0113-0.01130.0153-0.02910.50875.925.75125,750.00-37.44-8.02----17.4345.80-73.60-15.070.0774-2.512.26---2.800.9731-39.42--31.03--
Rua Life Sciences PLC5.17m-850.00k9.00m33.00--1.26--1.74-0.0137-0.01370.08320.11510.54591.186.23---9.18---10.42--77.10---16.82--3.87--0.0995--------------
Genedrive PLC954.00k-5.23m10.81m43.00--4.56--11.33-0.0093-0.00930.00170.00230.1984--1.8022,186.05-108.81-77.52-153.92-106.30-----548.32-1,016.121.64--0.00--90.42-2.0726.06---10.48--
Verici DX PLC1.40m-5.56m10.91m15.00--0.9642--7.81-0.0229-0.02290.00580.00750.2298--1.6777,631.66-91.48---119.40--81.60---398.12------0.102--229.62--32.75------
Cellbxhealth PLC2.62m-15.78m11.96m119.00--0.2897--4.56-0.0489-0.04890.00810.03620.10280.59391.4622,050.42-61.80-41.90-72.78-46.8162.2718.55-601.37-1,051.132.63-470.570.2387--30.92--29.34------
Abingdon Health PLC8.43m-3.42m15.06m121.00--2.19--1.79-0.0176-0.01760.04350.02741.179.713.8769,661.16-47.42-54.04-70.70-85.9144.3230.37-40.51-110.071.58--0.1625--37.399.99-168.69---26.92--
Inspiration Healthcare Group PLC45.20m-11.44m15.24m214.00--0.9312--0.3372-0.1275-0.12750.50380.18261.032.005.91211,215.00-25.96-6.05-33.03-7.4544.3946.62-25.32-7.011.112.420.441--1.6516.56-148.04--39.05--
Renalytix PLC2.19m-14.90m25.20m45.00------11.50-0.0594-0.05940.008-0.01540.45477.644.54---309.18-83.70---107.2540.0028.27-680.00-1,519.311.17-24.576.38--31.06--55.14------
Aptamer Group PLC1.20m-2.42m25.62m31.00--13.69--21.30-0.0014-0.00140.00070.00070.42946.274.3538,806.45-86.53---154.00--48.13---201.50--1.48-84.630.2622--39.88--18.05------
Aoti Inc46.65m1.72m44.41m80.0021.193.4312.950.95190.01970.01970.46870.12191.322.174.65--4.87--6.54--88.13--3.69--2.542.810.5269--32.88--78.55------
Ondine Biomedical Inc1.19m-12.88m46.80m43.00--102.33--39.42-0.0353-0.03530.00320.00090.34470.57718.03---373.83---4,807.85--65.77---1,084.66--0.7948--0.4333--70.32---32.51------
Creo Medical Group PLC2.20m12.60m72.60m133.005.951.195.2233.000.02960.02720.00560.14770.0319-0.80340.330816,541.3518.25-29.2520.62-35.8945.4547.22572.73-176.824.75-69.500.0645--0.00212.28-17.30---18.58--
Inspecs Group PLC192.83m-3.31m76.25m1.65k--0.85588.160.3954-0.0326-0.08061.900.87640.91382.317.71116,586.50-1.57-2.16-2.31-3.1351.8649.60-1.72-2.790.88471.730.3969---2.4832.80-362.19--4.97--
Data as of Feb 10 2026. Currency figures normalised to Aptamer Group PLC's reporting currency: UK Pound GBX

Institutional shareholders

7.28%Per cent of shares held by top holders
HolderShares% Held
Oberon Investments Ltd. (GB Investment Management)as of 13 Oct 2025172.05m6.38%
Lansdowne Partners (UK) LLPas of 20 Aug 202424.34m0.90%
Data from 30 Sep 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.